High dose methotrexate in chemotherapy for osteosarcoma of the extremities: 63 cases report

Bing ZHU,Su-jia WU,Zhen WANG,Xiu-chun YU,Ping SUN

DOI: https://doi.org/10.3969/j.issn.2095-252X.2015.05.009

2015-01-01

Abstract:Objective To provide a basis for the clinical application of high dose methotrexate ( HD-MTX ) through summarizing the effects of HD-MTX and analyzing its safety in a multicenter randomized controlled study on chemotherapy for osteosarcoma of the extremities.Methods The clinical data of 63 patients with osteosarcoma who were admitted by 5 domestic hospitals from February 2009 to December 2010 were collected,including 32 patients in the experimental group and 31 patients in the control group.A combined analysis of the data in both groups was performed in the multicenter randomized controlled study.According to the experimental design,the patients received unified and standardized administration,whose blood concentration was detected,and the corresponding laboratory examination was performed.The complications related to the application of HD-MTX and toxic reactions were retrospectively analyzed.The side effects were evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events ( CTCAE ) v4.0,including the liver,kidney,hematology and mucosal toxicity.Results Sixty of the 63 patients enrolled in this study received HD-MTX,and a total of 186 cycles were administered,with a mean dosage of 7.45 g / m2.The patients whose blood concentration was ＞20 μm accounted for 27.9％after 24 hr of administration,and 1％after 48 hr of administration.The overall disease free survival rate was 37.0％( 20 / 54 ),and the overall survival rate was 66.7％( 36 / 54 ).The maximum of glutamic-pyruvic transaminase ( GPT ) was 2133 mmol / L,which was ＞800 mmol / L for 4 times ( CTCAE 4 degrees ) and 200-800 mmol / L for 15 times ( CTCAE grade 3 ).The maximum of creatinine was 190 mmol / L ( CTCAE grade 2 ).Abnormal renal function was found in 4 cases ( CTCAE grade 2 ).The occurrence rate of sever liver injuries was 4.8％( 9 / 186 ).The occurrence rate of severe renal function damage was 2.2％( 4 / 186 ).There was 1 death case.No irreversible damage to the liver or kidney was found.The adverse reaction of cutaneous anaphylaxis at 1-24 hr after the administration was ifrstly noticed,and the occurrence rate was 18.8％( 6 / 32 ) among the recorded cases.The occurrence rates of myelosuppression Ⅰ-Ⅱ,myelosuppression Ⅳ and stomatitis were 45％,12％and 13.5％in the other 28 cases.There were no signiifcant differences in the occurrence rate or severity of renal and hepatic injuries and myelosuppression between the patients with anaphylaxis and the patients without anaphylaxis.The occurrence rate of gastrointestinal reactions in different degrees such as vomit,abdominal distension and diarrhea was ＞90％( CTCAE grade 1-4 ).Conclusions The application status of HD-MTX are summarized thoroughly in this study,which provides scientiifc data and a strong basis for the reasonability and safety in its clinical application.